Eledon Pharmaceuticals Inc
Research Eledon Pharmaceuticals Inc (ELDN) on Bullrun: market cap USD 280.69M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerELDN
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 280.69M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 39.03M
- Free cash flow-USD 22.61M
Valuation Snapshot
latest market cap is USD 280.69M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 45.62M | -USD 62.34M | n/a | -0.52 | USD 22.81M | USD 641.00K | USD 81.09M |
| FY2024 | USD 0 | -USD 36.18M | -USD 47.27M | n/a | -0.66 | USD 20.55M | USD 954.00K | USD 62.45M |
| FY2023 | n/a | -USD 116.54M | n/a | n/a | -4.73 | USD 4.61M | USD 383.00K | -USD 48.49M |
| FY2022 | n/a | -USD 87.97M | n/a | n/a | -6.16 | USD 56.41M | USD 586.00K | USD 23.79M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 280.69M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 113.90M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 246.33M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 43.56M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 31.37M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 63.09M | n/a | n/a | n/a |
About Eledon Pharmaceuticals Inc
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Eledon Pharmaceuticals Inc's market cap?
Eledon Pharmaceuticals Inc's market capitalization is USD 280.69M.
What does Eledon Pharmaceuticals Inc do?
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation.